Silica-based superhydrophobic coatings were produced on glass substrate by dip-coating process. Colloidal solutions containing nanoparticles of silica synthesized via seed growth method (single-and dual-sized particles) and dispersed in three different solvents, ethanol, silica sol and acidic silica sol, were used. Coatings with dual-sized particles in ethanol showed superhydrophobicity with a water contact angle of 155°. The coating adhesion was improved with the use of acidic silica sol as solvent. Coatings prepared from colloidal solution containing 30 wt.% of dual-sized silica particles of 600 and 800 nm in acidic silica sol, showed hydrophilicity with water contact angle of 45° before heat treatment due to the presence of-OH groups from acidic sol. After heat treatment at 250°C for 2 h in atmospheric ambience, the-OH groups reacted to form cross-linked Si-O-Si resulting in superhydrophobicity of the coating with water contact angle of 147°. In this work, silica based superhydrophobic coating was fabricated by adjusting the ratios of the dual-sized silica particles without carrying out any secondary step such as chemical modification or fluorination process on the coating.
BACKGROUND
The use of biodegradable polymer drug-eluting stents (BP-DES) has been proven to minimize restenosis and stent thrombosis. The current post-marketing monitoring was observed at the 5-year clinical outcomes of individuals who had been treated with FlexyRap
®
DES in the real world.
AIM
To assess the safety and effectiveness of FlexyRap
®
DES at the 5-year follow-up in real-world settings.
METHODS
Findings from a retrospective, multi-center, observational, post-market clinical follow-up study of patients treated with FlexyRap
®
DES for
de novo
coronary artery disease (CAD) were reported. During the 12-mo follow-up, the primary endpoint was target lesion failure, which was defined as the composite of cardiovascular death, target vessel myocardial infarction (TV-MI), and clinically driven target lesion revascularization.
RESULTS
The data of 500 patients received with FlexyRap
®
DES was obtained at the completion of the surveillance timeline of 5-year. After the implantation of FlexyRap
®
DES, the device success rate was 100%. Adverse events that led to major bleeding, permanent disability, or death were not experienced in the patients. The major adverse cardiac event rate at 12-mo, 3-year, and 5-year follow-up was 1 (0.2%), 0 (0%), and 1 (0.2%) respectively with 0 (0%) cardiovascular death, 2 (0.4%) TV-MI, and 0 (0%) TLR compositely. Furthermore, late stent thrombosis was found in 2 (0.4%) patients at the follow-up of 12-mo, very late stent thrombosis was observed in 2 patients (0.4%) at 3-year follow-up.
CONCLUSION
FlexyRap
®
DES was proved to be safe and efficacious in real-world patients with
de novo
CAD, indicating a lowered rate of cardiac events and stent thrombosis at 5-year follow-up.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.